-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'> Recently, Zhejiang Jianxin Force Pharmaceutical Co.
, Ltd.
("Jianxin Force"), a biomedical company based on innovation and partnerships, announced the completion of a round A financing of 625 million yuan (approximately US$96 million).
New Force will complete another milestone after the Pre-A round of financing of 170 million yuan (approximately US$24 million) in June 2020.
, Ltd.
("Jianxin Force"), a biomedical company based on innovation and partnerships, announced the completion of a round A financing of 625 million yuan (approximately US$96 million).
New Force will complete another milestone after the Pre-A round of financing of 170 million yuan (approximately US$24 million) in June 2020.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The A round of financing was jointly led by Zhongnan Venture Capital and Yanchuang Capital, and the original shareholders, Quanchuang Capital, etc.
continue to support it.
China Renaissance Capital acted as the exclusive financial advisor for this transaction.
The A round of financing was jointly led by Zhongnan Venture Capital and Yanchuang Capital, and the original shareholders, Quanchuang Capital, etc.
continue to support it.
China Renaissance Capital acted as the exclusive financial advisor for this transaction.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Jianxin Force warmly welcomes Mr.
Cai Jiongming of Zhongnan Venture Capital and Ms.
Liu Zeng of Yanchuang Capital to join the board of directors.
Jianxin Force warmly welcomes Mr.
Cai Jiongming of Zhongnan Venture Capital and Ms.
Liu Zeng of Yanchuang Capital to join the board of directors.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Mr.
Li Xuejun, Vice President of Zhongnan Venture Capital, said : "We are honored to have the opportunity to invest in Jianxin Force and its unique business model.
We believe that their creative biopharmaceutical development model will be proved by results.
"Mr.
Li Xuejun, Vice President of Zhongnan Venture Capital, said : “We are honored to have the opportunity to invest in Jianxin Force and its unique business model.
We believe their creative biopharmaceutical development model will be proved by results.
"544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Mr.
Lin Tao, Managing Director of Yanchuang Capital, said : "I am very pleased that this investment will accelerate the clinical development and commercialization of new therapies, promote the construction of drug production infrastructure, and support existing cooperation projects.
We manage the force of Jianxin The team’s rich experience in the development and production of biopharmaceuticals is very confident, and I believe they will live up to expectations and achieve results.
"Mr.
Lin Tao, Managing Director of Yanchuang Capital, said : "I am very pleased that this investment will accelerate the clinical development and commercialization of new therapies, promote the construction of drug production infrastructure, and support existing Cooperation projects.
We are confident in the rich experience of the Jianxin Force management team in the development and production of biopharmaceuticals, and believe that they will live up to expectations and achieve results.
"544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>This round of funding will accelerate the construction of Jianxin Force in Hangzhou, China, and provide global GMP biopharmaceutical production capacity, including the establishment of cell and gene therapy production capacity and a monoclonal antibody production facility in a joint venture with Thermo Fisher.
The company's business model will promote the development and commercialization of innovative drugs in China, the United States, Europe and other parts of the world for global customers and partners.
Jianxin Force will continue to create a biopharmaceutical ecosystem, provide tailor-made drug development, operation management and other services for partners, as well as extensive support for start-up companies.
This round of funding will accelerate the construction of Jianxin Force in Hangzhou, China, and provide global GMP biopharmaceutical production capacity, including the establishment of cell and gene therapy production capacity and a monoclonal antibody production facility in a joint venture with Thermo Fisher.
The company's business model will promote the development and commercialization of innovative drugs in China, the United States, Europe and other parts of the world for global customers and partners.
Jianxin Force will continue to create a biopharmaceutical ecosystem, provide tailor-made drug development, operation management and other services for partners, as well as extensive support for start-up companies.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Dr.
Wu Hui, Managing Director of Quanchuang Capital, said : “We have been shocked by the rich experience and execution ability of the Jianxin Force leadership team.
We are excited to support the company’s strategic development and are pleased to see Jiquan Capital After leading the Pre-A round of financing, more high-quality investors have full confidence in Jianxin Force.
"Dr.
Wu Hui, Managing Director of Quanchuang Capital, said : “We have been shocked by the rich experience and execution capabilities of the Jianxin Force leadership team.
We are excited about supporting the company’s strategic development.
And I am very pleased to see that more high-quality investors have full confidence in Jianxin Force following the lead investment of Pre-A round of financing by Quan Venture Capital.
"544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Dr.
Li Yuling, CEO of Jianxin Force further stated : “We look forward to Jianxin Force’s ability to provide cell and gene therapy and monoclonal antibody product production services to China and the world, innovate China, and benefit the world.
At the same time, we will provide various advanced technologies.
Biotechnology and innovative product development companies are introduced to the Jianxin Force Park to support their establishment and development, and win-win cooperation.
"Dr.
Yuling Li, CEO of Jianxin Force, further stated that Dr.
Yuling Li, CEO of Jianxin Force, further stated : "We look forward to expanding the ability of Jianxin Force to provide cell and gene therapy and monoclonal antibody product production services to China and the world, and to innovate in China.
Inclusive of the whole world.
At the same time, we have introduced various advanced biotechnology and innovative product development companies to the Jianxin Force Park to support their establishment and development, and win-win cooperation.
"544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The Phase I plant in Jianxin Force Park in Hangzhou will be delivered before the end of 2021, and all GMP production operations will be completed step by step as planned within 2022.
The process development laboratory and related facilities outside the park will be put into use in May 2021.
The core of the park will be the development capabilities of Jianxin Force technology and detection technology, as well as CDMO services for the production of plasmid DNA, viral vectors, cell and gene therapy products GMP.
In addition, the park also owns Thermo Fisher Scientific (Hangzhou) Co.
, Ltd.
, a joint venture with Thermo Fisher to produce antibodies and protein drugs globally.
The Phase I plant in Jianxin Force Park in Hangzhou will be delivered before the end of 2021, and all GMP production operations will be completed step by step as planned within 2022.
The process development laboratory and related facilities outside the park will be put into use in May 2021.
The core of the park will be the development capabilities of Jianxin Force technology and detection technology, as well as CDMO services for the production of plasmid DNA, viral vectors, cell and gene therapy products GMP.
In addition, the park also owns Thermo Fisher Scientific (Hangzhou) Co.
, Ltd.
, a joint venture with Thermo Fisher to produce antibodies and protein drugs globally.